Back to Hematology
Hematologyv2014Evidence-Based

Multiple Myeloma Diagnostic Criteria (IMWG)

Diagnoses multiple myeloma according to the International Myeloma Working Group (IMWG) criteria, including traditional CRAB criteria and newer SLiM biomarkers.

Clinical Input Parameters

Clinical Assessment
Awaiting Parameters
diagnosis
—Points
Ready to Calculate

Awaiting Clinical Input

Enter the clinical input parameters on the left and click Run Clinical Assessment to evaluate this medical calculator with deterministic clinical scoring.

Open in Web App
Clinical decision support tool for licensed medical practitioners. Confirm independently before prescribing or clinical action.

When & Why to Use

The Multiple Myeloma Diagnostic Criteria (IMWG) is utilized in clinical practice for risk stratification, diagnostic probability estimation, and treatment decision-making within hematology.

Use this tool during initial patient intake, emergency department workup, or bedside assessment when objective clinical scoring is required to guide management or admission decisions.

Clinical Formula & Scoring Logic

Multiple Myeloma Diagnosis = (Clonal plasma cells ≥10% OR Biopsy-proven plasmacytoma) AND ≥1 myeloma defining event (CRAB criteria: Hypercalcemia, Renal insufficiency, Anemia, Bone lesions; OR SLiM biomarkers: ≥60% plasma cells, Light chain ratio ≥100, >1 MRI focal lesion)

Clinical Pearls & Practice Notes

  • The IMWG criteria require both clonal plasma cell evidence AND myeloma defining events
  • Traditional CRAB criteria represent end-organ damage from multiple myeloma
  • SLiM biomarkers (2014 update) allow diagnosis before end-organ damage occurs
  • SLiM stands for: 60% plasma cells, Light chain ratio ≥100, MRI >1 focal lesion
  • CRAB stands for: Calcium elevation, Renal dysfunction, Anemia, Bone lesions
  • Clonal plasma cells must be confirmed by flow cytometry, immunohistochemistry, or immunofluorescence
  • Plasmacytoma diagnosis requires tissue biopsy confirmation
  • Hypercalcemia: >1 mg/dL above upper limit of normal or >11 mg/dL
  • Renal insufficiency: Creatinine clearance <40 mL/min or serum creatinine >2 mg/dL
  • Anemia: >2 g/dL below lower limit of normal or <10 g/dL
  • Bone lesions: One or more osteolytic lesions on skeletal radiography, CT, or PET-CT
  • Light chain ratio: Involved to uninvolved serum free light chain ratio ≥100
  • MRI focal lesions: More than one focal lesion on MRI studies
  • 60% plasma cells: Clonal bone marrow plasma cells ≥60%
  • Concurrent medical conditions may complicate the interpretation of these criteria
  • Additional testing may include serum protein electrophoresis, immunofixation, and cytogenetics
  • The criteria distinguish multiple myeloma from MGUS and smoldering multiple myeloma
  • Early treatment may prevent progression to symptomatic multiple myeloma
  • Requires comprehensive hematologic evaluation and multidisciplinary care
  • Regular monitoring is essential for patients meeting diagnostic criteria

Evidence & Literature Citations

  1. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-48. doi: 10.1016/S1470-2045(14)70442-5.
  2. Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.
  3. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33(26):2863-9. doi: 10.1200/JCO.2015.61.2267.

Score Interpretation Ranges

Not Diagnostic0 – 0 pts

Criteria not met for multiple myeloma

Multiple Myeloma1 – 1 pts

Criteria met for multiple myeloma

Need Clinical Suite Access?

Run this calculator with patient history, laboratory integration, and drug interaction safety checks on the DexaMed clinician app.

Open in Web App

Clinical Decision Support (CDS) Notice & Legal Disclaimer

This medical calculator and its scoring interpretation are provided strictly for licensed healthcare professionals and medical trainees as an educational and clinical decision support instrument. It does not replace independent clinical judgment, comprehensive patient history, physical examination, or attending physician oversight. Not FDA-cleared as an autonomous diagnostic medical device. Read the full DexaMed Medical Disclaimer.